Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Naoko Kanda"'
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 7 (2024)
Externí odkaz:
https://doaj.org/article/9a81df5a6d3c4646adef5bb9647b75f7
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBackground Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD).Objectives To assess the effectiveness and safety of upadacitinib throug
Externí odkaz:
https://doaj.org/article/125f79157b5a401989a79eef97ab3dac
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBackground Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor recently approved for psoriasis.Objectives We aimed to evaluate the real-world effectiveness and safety of deucravacitinib for psoriasis.Methods We analyzed 33
Externí odkaz:
https://doaj.org/article/bee7e5b6c5b6473c9b2e62897843c709
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBackground Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors for high responders to upadacitinib have not been established in real-world clinical practice.Objectives To
Externí odkaz:
https://doaj.org/article/5e5f45902c4c465e8fed0e92cd574477
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBackground Though Janus kinase inhibitors such as upadacitinib rapidly relieve itch in atopic dermatitis (AD) patients, how early itch relief impacts later skin clearance is not examined.Objectives This study aims to determine if early itch r
Externí odkaz:
https://doaj.org/article/fff11d21c56246bd96a6f5a85cb289c6
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundAtopic dermatitis (AD) is a chronic skin disease characterized by type 2-skewed immune responses, and significantly influenced by cytokines dependent on Janus kinases (JAKs). Upadacitinib, a JAK1 inhibitor, is effective for moderate-to-seve
Externí odkaz:
https://doaj.org/article/b0528a7acdf5437197aca98cefd9bf69
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
AbstractBackground Atopic dermatitis (AD) is a chronic eczematous disease with severe pruritus. Janus kinase (JAK) inhibitors, upadacitinib, baricitinib, and abrocitinib, are systemic treatments for AD. The outcomes of switching from one JAK inhibito
Externí odkaz:
https://doaj.org/article/160f4b5d0f8442798a360cd2f1185863
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Upadacitinib is an oral Janus kinase (JAK) 1 inhibitor approved in Japan for moderate-to-severe atopic dermatitis (AD), and it provides a high therapeutic efficacy. Objectives We compared the therapeutic effects of upadacitinib on skin ras
Externí odkaz:
https://doaj.org/article/58823bb17a484021ac77db4aeaca39a4
Publikováno v:
Pharmaceuticals, Vol 17, Iss 4, p 519 (2024)
Clinical trials and real-world studies have shown the effectiveness of upadacitinib for treating rash and pruritus in patients with atopic dermatitis (AD). This study aimed to determine whether the early reduction in rash or pruritus at week 12 of up
Externí odkaz:
https://doaj.org/article/4a5942bc25094703b3daf94c70c65891
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 4, Iss 5, Pp 149-150 (2021)
Externí odkaz:
https://doaj.org/article/cd67de0ed1314b13b2e1e62003fb6184